We’d love to hear your feedback on this activity. It helps us to continually improve our products.
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Ahmed Kaseb, MD, is a Professor and Program Director of Hepatocellular Carcinoma (HCC), in the Department of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Dr Kaseb received his medical degree from Cairo University, and worked as a research fellow at the University of Michigan in Ann Arbor, MI, USA, for two years focusing on cancer biomarkers before starting his internal medicine residency at Wayne State University, Detroit, also in MI, where he excelled in clinical training and was the recipient of The Best Resident Award in 2003–2004. read more
He then finished a medical oncology fellowship at Henry Ford Hospital, Detroit, MI, where he continued his translational research work, which led to three major publications presenting circulating biomarkers for early cancer detection in the area of bladder and prostate cancers and his work on HCC biomarkers was subsequently initiated. Dr Kaseb’s work has received international awards from the American Society of Clinical Oncology (ASCO) and the American College of Physicians (ACP).
Dr Kaseb joined the department of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center in 2007 to lead the HCC program. Dr Kaseb is heavily involved in HCC clinical research, where he has served as principal investigator on multiple clinical trials. Dr Kaseb’s principal research interests include HCC systemic and multidisciplinary therapies, in addition to molecular staging studies. His research also examines the differential effects of demographics and hepatitis status on treatment outcomes in HCC. Based on his interests and research, he has developed several protocols in the treatment and staging of HCC. Dr Kaseb’s work has contributed greatly to the understanding of HCC interdisciplinary therapies and molecular staging, and has received governmental and pharmaceutical funding for several projects and clinical trials.
Dr Kaseb has extensively authored and co-authored dozens of papers and books. He also serves as an editor and scientific reviewer for several international medical journals. Dr Kaseb is an active member of several international societies and has served on several committees and advisory boards at national and international levels, and has also participated in several international expert consensus conferences in the area of HCC.
Prof. Ahmed Kaseb discloses: Advisory board/panel fees from AstraZeneca, Bristol Myers Squibb, Eisai, Merck and Roche/Genentech; Consultancy fees from AstraZeneca, Bristol Myers Squibb, Eisai, Merck and Roche/Genentech; and Grants/research support from AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Exelixis, Merck and Roche/Genentech.
Yonsei University, Seoul, Korea
Jinsil Seong, MD, PhD, is a Professor in the Department of Radiation Oncology at Yonsei University Medical College in Seoul, Korea. Currently, she is also President of the Asia Pacific Primary Liver Cancer Expert (APPLE) Association and Executive Board member for the Asian Oncology Society. Prof. Seong completed her medical training and PhD at Yonsei University in Seoul, Korea. Prior to her current position, Prof. Seong was a visiting scientist in the Department of Experimental Radiotherapy at MD Anderson Cancer Center in Texas, USA. read more
Prof. Seong maintains active memberships in numerous professional or academic societies, including the National Academy of Medicine of Korea, the International Liver Cancer Association and the Asia Pacific Association for the Study of the Liver. She was awarded the Cancer Prevention Award from the Korean Ministry of Health and Welfare for her contribution on HCC prevention by establishing Liver Cancer Day for the first time in Korea. She received the Adrienne Wilson Liver Cancer Association’s Blue Faery Award for Excellence in Liver Cancer Research for her pioneering work in radiotherapy for HCC, as well as other domestic academic awards (Beum-Suk Best Researcher Award, Joong-Wei Best Academic Award, Yonsei University Medical College Best International Collaboration Award).
Prof. Seong sits on the editorial board for the Journal of Hepatology, has published over 200 journal articles in international peer-reviewed journals, and contributed to several book chapters on the use of radiation therapy. She is a frequent invited speaker at academic conferences and educational events across Asia and the world.
Dr Jinsil Seong has no financial interests/relationships or affiliations in relation to this activity.
University of Mainz, Mainz, Germany
Dr Galle, MD, PhD, majored in internal medicine at the Universities of Berlin, Marburg, Mannheim and Heidelberg, Germany, at Hammersmith Hospital, London, UK, as a Fulbright grantee at the University of Texas, USA. He received his MD degree from Marburg University and PhD degree from Heidelberg University, both in Germany. Initially, he held a position as postdoctoral fellow in Molecular Biology at the Centre for Molecular Biology of Heidelberg, working on the replication of hepatitis B viruses. Afterwards, he completed his residency in Internal Medicine and Gastroenterology at the University Hospital of Heidelberg. In 1998, he became director of the Internal Medical Department in Mainz, and from 2005–2008 he was CEO of Mainz University Hospital. read more
He is a member of several national and international societies, such as the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL), has served as co-editor for the Journal of Hepatology and is on the editorial boards of several other journals. He served as congress president of the German Society for Digestive Diseases (DGVS) in 2014. He was a member of the Executive Board and President of the International Liver Cancer Association (ILCA). He was the President of the German Association for the Study of the Liver (GASL) for the year 2020.
His research has focused on elucidating important aspects of apoptotic cell death in the liver, immune escape of tumour cells and on clinical and molecular aspects of HCC. He chaired the panel updating the EASL Clinical Practice Guideline on HCC, which was published in 2018. He has been awarded several prizes, including the prestigious Tannhauser Award, the highest prize of the DGVS. He has published more than 500 peer-reviewed papers.
Prof. Peter Galle discloses: Consultancy fees from AstraZeneca, Bayer, Bristol Myers Squibb, Ipsen, Lilly, Merck, Sharp & Dohme, Roche, SillaJen and Sirtex Medical.
Banner MD Anderson Cancer Center, Phoenix, AZ, USA
Michael Choti, MD, received his MD degree at Yale University, New Haven, general surgery training at the University of Pennsylvania, Philadelphia, and completed a surgical oncology fellowship at Memorial Sloan-Kettering Cancer Center, New York, before joining the Division of Surgical Oncology at Johns Hopkins, Baltimore. Among his leadership roles, he was the Chair of Surgery at the University of Texas Southwestern Medical Center. Currently, he is the Chief of Surgery at Banner MD Anderson Cancer Center in Phoenix, Arizona, USA. read more
Dr Choti is an active clinician and researcher with an interest in new approaches for the treatment of liver, pancreatic, and colorectal cancer. He has served in various leadership positions in national and international societies and has chaired study sections for the American Cancer Society. He served as chair of the National Cancer Institute’s Cancer Therapy Evaluation Program (NCI-CTEP) Hepatobiliary Task Force and as the director of the National Comprehensive Cancer Network (NCCN) Neuroendocrine Tumor database, as well as serving on the American College of Surgeons Commission on Cancer, the gastrointestinal committees of the National Surgical Adjuvant Breast and Bowel Project (NSABP) and the American College of Surgeons Oncology Group (ACOSOG), and the Colorectal Cancer and Neuroendocrine Tumors Guidelines Panels of NCCN. He has directed educational symposia and served on program committees for the American Society of Clinical Oncology (ASCO), Society of Surgical Oncology (SSO), and American Association for Cancer Research (AACR), among others. He was also a section editor for the Annals of Surgical Oncology, and he has served on the surgical oncology board for the American Board of Surgery.
Dr Michael Choti discloses: Consultancy fees from Merck Sharp & Dohme.
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Or use a
.Explore the latest in medical education and stay current in your field. Create a free account to track your learning.